about
Heat shock proteins 70 and 60 share common receptors which are expressed on human monocyte-derived but not epidermal dendritic cellsBirbeck granules are subdomains of endosomal recycling compartment in human epidermal Langerhans cells, which form where Langerin accumulatesPlatelets and arterial thrombosisPlatelet glycoprotein V binds to collagen and participates in platelet adhesion and aggregationA study of platelet activation in atrial fibrillation and the effects of antithrombotic therapyCloning and characterization of the gene encoding the human platelet glycoprotein V. A member of the leucine-rich glycoprotein family cleaved during thrombin-induced platelet activationA role of the fast ATP-gated P2X1 cation channel in thrombosis of small arteries in vivoInhibition of platelet functions and thrombosis through selective or nonselective inhibition of the platelet P2 receptors with increasing doses of NF449 [4,4',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis-(carbonylimino)))tetrakis-benzene-1,3-diImportance of platelet phospholipase Cgamma2 signaling in arterial thrombosis as a function of lesion severity.MRS2500 [2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate], a potent, selective, and stable antagonist of the platelet P2Y1 receptor with strong antithrombotic activity in miceTransfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial.Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set.[Blood platelets: conclusion].Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null miceCommon characteristics of the human and rhesus macaque CD1e molecules: conservation of biochemical and biological properties during primate evolution.The cellular pathway of CD1e in immature and maturing dendritic cells.The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells.Assistance of microbial glycolipid antigen processing by CD1e.Synthesis and biological evaluation of PEG-tirofiban conjugates.A new ELISA kit which uses a combination of Plasmodium falciparum extract and recombinant Plasmodium vivax antigens as an alternative to IFAT for detection of malaria antibodies.Rab11A controls the biogenesis of Birbeck granules by regulating Langerin recycling and stability.The P2Y(1) receptor is involved in the maintenance of glucose homeostasis and in insulin secretion in mice.Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period.Proteome changes in platelets after pathogen inactivation--an interlaboratory consensus.The antithrombotic activity of EP224283, a neutralizable dual factor Xa inhibitor/glycoprotein IIbIIIa antagonist, exceeds that of the coadministered parent compounds.HLA-DQA2 and HLA-DQB2 genes are specifically expressed in human Langerhans cells and encode a new HLA class II molecule.The assembly of CD1e is controlled by an N-terminal propeptide which is processed in endosomal compartments.Cutting edge: a naturally occurring mutation in CD1e impairs lipid antigen presentation.Reproduction of Langerin/CD207 traffic and Birbeck granule formation in a human cell line model.A novel missense mutation shows that GPIbbeta has a dual role in controlling the processing and stability of the platelet GPIb-IX adhesion receptor.Novel antagonists acting at the P2Y(1) purinergic receptor: synthesis and conformational analysis using potentiometric and nuclear magnetic resonance titration techniques.Microgravity modifies protein kinase C isoform translocation in the human monocytic cell line U937 and human peripheral blood T-cells.An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment.Platelet phospholipids are differentially protected against oxidative degradation by plasmalogens.A Leu7Pro mutation in the signal peptide of platelet glycoprotein (GP)IX in a case of Bernard-Soulier syndrome abolishes surface expression of the GPIb-V-IX complex.A general approach toward the synthesis of C-nucleoside pyrazolo[1,5-a]-1,3,5-triazines and their 3',5'-bisphosphate C-nucleotide analogues as the first reported in vivo stable P2Y(1)-receptor antagonists.Kinetics of gene induction after FcepsilonRI ligation of atopic monocytes identified by suppression subtractive hybridization.Role of the intracellular domains of GPIb in controlling the adhesive properties of the platelet GPIb/V/IX complex.Differential involvement of the P2Y1 and P2Y12 receptors in platelet procoagulant activity.Identification of a novel 14-3-3zeta binding site within the cytoplasmic tail of platelet glycoprotein Ibalpha.
P50
Q24292217-0B855BE8-4676-4BD5-BD8F-D2BF78399C26Q24555038-2F4AB1CC-1E27-43DD-9769-A7C4FCD164E9Q28165639-5C627786-F86C-4E52-9B75-BC9C47640658Q28187729-2EC80DF0-F713-48B4-BFED-2A24482AF79AQ28194127-E89F45D1-20CD-4723-89A8-C3FBCE73BC6AQ28264692-621B7159-A298-4DDC-B8FC-0F3FF7A8145FQ28513773-3E67833C-69AC-4B4F-9534-E185E0D0949EQ30780555-B30D2967-CAD6-488E-A106-39B755836E7CQ33213016-3AA0EBCE-39A3-45A5-9B4A-0965769797DEQ33225547-FE8C769F-5537-4FD4-A82D-0530A9274545Q33345486-DD5F634C-50FB-4431-B5F0-AA921E026FD3Q33368170-A2AA7AB0-C26C-4309-8338-0CE931E47057Q33415877-976C1EE5-27A4-42FC-8374-5E3A08B4FA87Q33903557-E2D6702E-B001-4774-857C-785FE5413A22Q34187823-FD968AFB-3A6F-4E83-8271-AE6C90615D43Q34400707-20C57810-4F5A-421D-985A-58D385C19262Q34416899-BD8B0841-5223-4432-800E-03AF2F683D7BQ34470656-FFB5CCC3-6337-40EE-BDB6-2B1FD8DB6500Q34588847-D95F4673-B9D8-4D4E-B422-C0CACE7AAC48Q35674855-BF156AF5-072A-4E7F-870A-2DAA22D374B3Q35942431-20CCF607-92D3-4325-913C-380CA10A094EQ36173756-87AAEC4B-125C-4044-9645-5237F53C7E85Q37789774-264C9E58-8376-43C2-B714-E851685F37CCQ38200776-2427503C-7554-47CF-86EB-C158DCE7F2B1Q38335613-9C1948C4-87E6-4885-BD64-FF0DE96E6F1FQ39381555-3F851F42-947E-4CF4-BD98-B0371F7BE785Q39887047-385B8662-FC23-4491-89A4-E52BB89F4BD5Q40004847-CEA32E24-C6E1-43C8-8FAF-F88ABB5F3764Q40546882-A61194F6-E501-4A59-A64B-2D811B74E8F7Q40655687-C949D1BD-FCF7-44E1-9EE2-945B580F821AQ40661908-FA6A40BD-A01D-4928-9C09-1107445893DBQ40706669-94C8DBEF-205B-4C1D-B271-84DEFFD97ED8Q43180389-6138ADEA-7681-4DF5-AEC8-B93FF76FBE66Q43953200-217D0055-FD8C-45E9-BAA1-61B197D69F2DQ44051884-B4C6495C-BBD1-4072-97AE-8D5431D905C9Q44210114-3BE6647B-5A46-4DB0-9F4D-EE5D2C1FF0B9Q44223887-A8B03FE1-6D7B-4A6C-9124-9E433999D410Q44274490-9411D355-2498-4180-8613-FE7ACABDB5C0Q44559216-DAE09D2B-B33D-4BC3-97D8-926E15167592Q44822030-3CF62BF5-1555-4F22-BDF0-7CFBBFF8EC4D
P50
description
hematólogo francés
@es
hematólogu francés
@ast
hulumtues
@sq
researcher
@en
ricercatore
@it
taighdeoir
@ga
հետազոտող
@hy
طبيب أمراض الدم فرنسي
@ar
name
Jean-Pierre Cazenave
@ast
Jean-Pierre Cazenave
@ca
Jean-Pierre Cazenave
@en
Jean-Pierre Cazenave
@es
Jean-Pierre Cazenave
@fr
Jean-Pierre Cazenave
@nl
Jean-Pierre Cazenave
@sl
type
label
Jean-Pierre Cazenave
@ast
Jean-Pierre Cazenave
@ca
Jean-Pierre Cazenave
@en
Jean-Pierre Cazenave
@es
Jean-Pierre Cazenave
@fr
Jean-Pierre Cazenave
@nl
Jean-Pierre Cazenave
@sl
prefLabel
Jean-Pierre Cazenave
@ast
Jean-Pierre Cazenave
@ca
Jean-Pierre Cazenave
@en
Jean-Pierre Cazenave
@es
Jean-Pierre Cazenave
@fr
Jean-Pierre Cazenave
@nl
Jean-Pierre Cazenave
@sl
P1006
P244
P269
P1006
P106
P1207
n2017047409
P19
P2038
Jean_Pierre_Cazenave
P21
P213
0000 0000 2865 5499
0000 0001 4058 5881
P214
P244
P269
P27
P31
P569
1943-05-06T00:00:00Z
P735
P7859
lccn-n85305431